Oryzon Genomics S.A. (0RDB.L) Stock Price
€2.83 0.5%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
6 -
Technical
5
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Oryzon Genomics S.A., AI stock picks, stock alerts and much more.
0RDB.L AI Stock Analysis
AI stock analysis for 0RDB.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Oryzon Genomics S.A. (0RDB.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Oryzon Genomics S.A. (0RDB.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Oryzon Genomics S.A. (0RDB.L), currently trading at €2.83, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About 0RDB.L
-
Oryzon Genomics S.
-
Symbol
0RDB.L
-
Market
LSE
-
Industry
Medical - Pharmaceuticals
-
Market Cap
219.4M
Similar Stocks
 |
Vertex Pharmaceuticals Incorporated 0QZU.L |
$471.7 0.2% |
7 |
 |
Neurocrine Biosciences 0K6R.L |
$133.5 0.1% |
7 |
 |
Emergent BioSolutions Inc. 0IGA.L |
$7.49 3% |
5 |
 |
Abeona Therapeutics Inc. 0H7R.L |
$5.85 1.5% |
5 |
 |
Walgreens Boots Alliance 0LSZ.L |
$11.48 0.4% |
5 |
News
0RDB.L Alternative Data
Web Traffic
Oryzon Genomics S.A. receives an estimated 10758 monthly visitors to oryzon.com, which is up by 66.2% over the last month.
-
Web Traffic
10758
-
Change from Previous Month
66.2%
-
3 Month Change
7.7%
-
YoY Change
7.7%
Job Postings
Oryzon Genomics S.A. currenly has an estimated 0 open job postings.
-
Job Postings
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Reddit Mentions
Oryzon Genomics S.A. has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Followers
9,893 are following Oryzon Genomics S.A. on LinkedIn, up by 1.2% over the last month.
-
LinkedIn Followers
9893
-
Daily Change
1.2%
-
1 Month Change
1.2%
-
3 Month Change
3.1%
Business Outlook
According to employee reviews, the business outlook among employees at Oryzon Genomics S.A. is 29 out of 100 (bearish).
-
Business Outlook
29
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
LinkedIn Employees
According to LinkedIn, Oryzon Genomics S.A. has 58 employees.
-
LinkedIn Employees
58
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
3.6%
News Mentions
Oryzon Genomics S.A. was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
0RDB.L Financials
0RDB.L Key Metrics
-
Total Revenue
$0
-
Net Income
$113K
-
Earnings per Share
$0.0018
-
Free cash flow
$0
-
EBITDA
$3.7M
-
EBITDA Ratio
0
-
Total Assets
$118.6M
0RDB.L 2-year Revenue & Income
0RDB.L 2-year Free Cash Flow
0RDB.L Technicals
0RDB.L SMA
0RDB.L RSI
FAQ
What's the current price of Oryzon Genomics S.A. (0RDB.L) Stock?
The price of an Oryzon Genomics S.A. (0RDB.L) share is €2.83.
What's the market cap of Oryzon Genomics S.A.?
The current market cap of Oryzon Genomics S.A. is 219.4M.
Should I buy or sell 0RDB.L?
Oryzon Genomics S.A. shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Oryzon Genomics S.A. is better viewed as a hold or accumulate position while waiting for further developments.
Is Oryzon Genomics S.A. a good investment?
The current analysis of Oryzon Genomics S.A.'s fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Oryzon Genomics S.A.'s portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Oryzon Genomics S.A. (0RDB.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Oryzon Genomics S.A. stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Oryzon Genomics S.A. (0RDB.L) that investors often compare it to?
Oryzon Genomics S.A. (0RDB.L) is often compared to similar stocks such as Vertex Pharmaceuticals Incorporated, Neurocrine Biosciences, Emergent BioSolutions Inc., Abeona Therapeutics Inc. and Walgreens Boots Alliance.
What is the forecast for Oryzon Genomics S.A.'s stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Oryzon Genomics S.A.'s stock price to be around €2.91 in 2026. Starting from the current price of €2.83, this represents a 2.8% change in price, indicating a neutral outlook for the stock.
How to buy Oryzon Genomics S.A. (0RDB.L) Stock?
Oryzon Genomics S.A. stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Oryzon Genomics S.A. shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.